Dan Ollendorf is chief scientific officer and director of health technology assessment (HTA) methods and engagement at the Institute for Clinical and Economic Review (ICER), with responsibility for managing the organisation’s internal health economics capacity and program of external collaboration, as well as collaboration with international HTA bodies and other stakeholders on key process and methods topics.

From 2007 to 2018, Dr. Ollendorf was chief scientific officer for ICER, where he oversaw the broader HTA process and managed relationships with multiple stakeholders and research collaborators. From 2018 to 2023, Dr. Ollendorf served as the director of value measurement and global health initiatives at the Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts Medical Center, where he focused on value assessment methods, drug pricing policy, and building international capacity for and interest in HTA. In addition to his current role at ICER, Dr. Ollendorf maintains a faculty appointment at CEVR and continues to teach in the center’s graduate certificate program as well as participate in ongoing research.

Dr. Ollendorf is also a non-resident fellow in Global Health at the Center for Global Development and serves on the board of directors for the ISPOR, the Professional Society for Health Economics and Outcomes Research. From 2019 to 2024, he served as chair of the health technology assessment international (HTAi) global policy forum. Dr. Ollendorf received his PhD in clinical epidemiology from the University of Amsterdam, and an MPH in health policy and management/epidemiology from Boston University.